Cresco Labs (CRLBF) Amortization of Deferred Charges (2020 - 2026)
Cresco Labs' (CRLBF) quarterly Amortization of Deferred Charges came in at $635000.0 in Q1 2026, down 47.56% YoY from $1.2 million in Q1 2025, and down 1.7% on a QoQ basis from $646000.0 in Q4 2025.
Cresco Labs (CRLBF) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Cresco Labs (CRLBF) has 7 years of Amortization of Deferred Charges data on file, last reported at $635000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges fell 47.56% year-over-year to $635000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (down 49.73% YoY) and the FY2025 annual result came in at $4.1 million, down 41.15% from the prior year.
- Amortization of Deferred Charges fell to $635000.0 in Q1 2026, from $646000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $3.2 million in Q4 2024 to a low of $517000.0 in Q3 2025.
- A 5-year average of $1.2 million and a median of $1.1 million in 2023 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges plunged 86.35% — and 2024, when it surged 179.57%.
- Tracing CRLBF's Amortization of Deferred Charges over 5 years: stood at $1.0 million in 2022, then advanced by 14.97% to $1.2 million in 2023, then jumped by 179.57% to $3.2 million in 2024, then tumbled by 80.08% to $646000.0 in 2025, then dropped by 1.7% to $635000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $635000.0 (Q1 2026), $646000.0 (Q4 2025), and $517000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Cresco Labs | 290.46 Mn | 226.34 Mn | 86.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 635,000.00 |
| Mar 31, 2026 | 635,000.00 |
| Dec 31, 2025 | 646,000.00 |
| Dec 31, 2025 | 646,000.00 |
| Sep 30, 2025 | 517,000.00 |
| Sep 30, 2025 | 517,000.00 |
| Jun 30, 2025 | 1.69 Mn |
| Jun 30, 2025 | 1.69 Mn |
| Mar 31, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.21 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Sep 30, 2024 | 1.26 Mn |
| Sep 30, 2024 | 1.26 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.18 Mn |
| Mar 31, 2024 | 1.18 Mn |
| Dec 31, 2023 | 1.16 Mn |
| Dec 31, 2023 | 1.16 Mn |